Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation
Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost
Express News | Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Nexiguran Ziclumeran (Nex-Z) for the Treatment of Hereditary Transthyretin (Attr) Amyloidosis With Polyneuropathy
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (Nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis With Polyneuropathy
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
三和巴菲特 : Have you cried today? Baby
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 :
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 : Laughed.
71179109 : Intellia - 20% yesterday